$Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction$

Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

Journal of Medical Economics

Saved in:

Bibliographic Details
Main Authors:	Lin L, Wu DBC, Abdul Aziz MI, Wong R, Sim D, Leong G, Yong QW, Tan D, Kwong N
Other Authors:	PHARMACY
Format:	Article
Published:	2020
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/176996
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
by: Rungroj Krittayaphong, et al.
Published: (2018)

Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
by: Rungroj Krittayaphong, et al.
Published: (2019)

Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
by: Rungroj Krittayaphong, et al.
Published: (2022)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
by: Tay, Wan Ting, et al.
Published: (2023)

Large animal models of heart failure: Reduced vs. preserved ejection fraction
by: Charles, C.J., et al.
Published: (2021)

Obesity and heart failure with preserved ejection fraction
by: Wattana Leowattana
Published: (2020)

Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs
by: Chen, Y.-T., et al.
Published: (2021)

Effect of a comprehensive heart failure treatment program on left ventricular ejection fraction and six-minute walk distance in heart failure patients with reduced ejection fraction at Lampang Hospital
by: Boonyapiphat T, et al.
Published: (2020)

Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020)

Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020)

Circulating neuregulin1-? in heart failure with preserved and reduced left ventricular ejection fraction
by: Hage, C., et al.
Published: (2021)

Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand
by: Kittayaporn Chairat, et al.
Published: (2020)

Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction
by: Rungroj Krittayaphong, et al.
Published: (2020)

Heart failure with preserved ejection fraction in women: The dutch queen of hearts program
by: den Ruijter H, et al.
Published: (2016)

Association of Prior Left Ventricular Ejection Fraction with Clinical Outcomes in Patients with Heart Failure with Midrange Ejection Fraction
by: Alison Brann, et al.
Published: (2020)

Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease
by: Nakkawee Saengklub, et al.
Published: (2022)

Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial
by: Lam, C.S.P., et al.
Published: (2016)

Cornell product is an ECG marker of heart failure with preserved ejection fraction
by: Tan, Eugene SJ, et al.
Published: (2023)

Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry
by: Chanchal Chandramouli, et al.
Published: (2020)

Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence
by: Huang, W., et al.
Published: (2021)

Endothelial dysfunction: A pathophysiologic factor in heart failure with preserved ejection fraction
by: Lam, C.S.P., et al.
Published: (2016)

Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction
by: Bai, B., et al.
Published: (2021)

Thymosin beta-4 is elevated in women with heart failure with preserved ejection fraction
by: Drum C.L., et al.
Published: (2020)

Relationship between Serum Dehydroepiandrosterone Levels and Heart Ejection Fraction in Heart Failure Patients
by: Rima Hayyu Chrisnanda, -, et al.

Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
by: Rungroj Krittayaphong, et al.
Published: (2022)

Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
by: Krittayaphong R.
Published: (2023)

Usefulness of Serum Biomarkers of Endothelial Glycocalyx Damage in Prognosis of Decompensated Patients with Heart Failure with Reduced Ejection Fraction
by: Yong Hyun Kim, et al.
Published: (2022)

Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic asian patients with heart failure with reduced ejection fraction
by: Vera J. Goh, et al.
Published: (2019)

Usefulness of Serum Biomarkers of Endothelial Glycocalyx Damage in Prognosis of Decompensated Patients with Heart Failure with Reduced Ejection Fraction
by: Kim Y.H.
Published: (2023)

Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation
by: Tantisuwat L.
Published: (2023)

Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand
by: Teng, Tiew-Hwa Katherine, et al.
Published: (2023)

2022 HFCT Focused Update of the 2019 HFCT Heart Failure Guidelines: Part 1 - Heart Failure Classification and Pharmacological Treatment for Heart Failure with Reduced Ejection Fraction (HFrEF)
by: Ariyachaipanich A.
Published: (2023)

The Effectiveness of Non-Pharmacological Interventions in Patients with Heart Failure with Preserved Ejection Fraction
by: AMANDA TAN LI YEE
Published: (2021)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Sweeney, M., et al.
Published: (2021)

Complete right bundle branch block predicts mortality in Thai patients with chronic heart failure with reduced ejection fraction
by: Wongcharoen W., et al.
Published: (2014)

Complete right bundle branch block predicts mortality in Thai patients with chronic heart failure with reduced ejection fraction
by: Wanwarang Wongcharoen, et al.
Published: (2018)

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry
by: MacDonald, M.R., et al.
Published: (2021)

Dapagliflozin Use in Heart Failure with Reduced Ejection Fraction Accompanied by Type 2 Diabetes Mellitus: A Systematic Review
by: Sinta Dwi Juniar, -, et al.
Published: (2022)

Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction
by: Yap, J., et al.
Published: (2021)

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
by: Pooja Dewan, et al.
Published: (2020)